CPT codes

53867 CPT codes with hospital pricing data in the network.

• CPT 488T — DIABETES PREV ONLINE/ELEC (84 hospitals, — samples)
• CPT 488U — Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antige (85 hospitals, — samples)
• CPT 489T — REGN CELL TX SCLDR HANDS (85 hospitals, — samples)
• CPT 489U — Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular count (85 hospitals, — samples)
• CPT 48U — ONC SLD ORG NEO DNA 468 GENE (85 hospitals, — samples)
• CPT 490T — REGN CELL TX SCLDR H MLT INJ (85 hospitals, — samples)
• CPT 490U — Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma-associated antigen, CD34 and CD45 protein biomarkers, peripheral blood (85 hospitals, — samples)
• CPT 49189 — OPN EXC/DST NTRA-ABD 20.1-30 (512 hospitals, — samples)
• CPT 491T — Laser Treatment Of Open Wound, First 20 Sq Cm Or Less (10 hospitals, — samples)
• CPT 491U — Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen r (85 hospitals, — samples)
• CPT 492T — Laser Treatment Of Open Wound, Each Additional 20 Sq Cm (7 hospitals, — samples)
• CPT 492U — Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 prot (85 hospitals, — samples)
• CPT 493T — Contact Near-Infrared Spectroscopy Of Wound Of Leg (7 hospitals, — samples)
• CPT 493U — Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA (85 hospitals, — samples)
• CPT 494T — PREP & CANNULJ CDVR DON LUNG (85 hospitals, — samples)
• CPT 494U — Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative (85 hospitals, — samples)
• CPT 495T — MNTR CDVR DON LNG 1ST 2 HRS (85 hospitals, — samples)
• CPT 495U — Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm report (85 hospitals, — samples)
• CPT 496T — MNTR CDVR DON LNG EA ADDL HR (85 hospitals, — samples)
• CPT 496U — Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk (85 hospitals, — samples)
• CPT 497T — Connection Of External Patient-Activated Ekg Event Recorder (7 hospitals, — samples)
• CPT 497U — Oncology (prostate), mRNA gene-expression profiling by real-time RT-PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer (85 hospitals, — samples)
• CPT 498T — Review And Interpretation Of External Patient-Activated Ekg Event Recordings (7 hospitals, — samples)
• CPT 498U — Oncology (colorectal), next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation (85 hospitals, — samples)
• CPT 499T — Examination Of Bladder And Urethra With Mechanical Dilation And Drug Delivery For Narrowing Of Urethra Using An Endoscope (10 hospitals, — samples)
• CPT 499U — Oncology (colorectal and lung), DNA from formalin-fixed paraffin-embedded (FFPE) tissue, next-generation sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection (85 hospitals, — samples)
• CPT 49U — NPM1 GENE ANALYSIS QUAN (85 hospitals, — samples)
• CPT 4A — Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19]) Vaccine, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted; Booster Dose (7 hospitals, — samples)
• CPT 4M — SCOLIOSIS DNA ALYS (82 hospitals, — samples)
• CPT 500U — Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.118-9_118-2del, S56F, S621C) (85 hospitals, — samples)
• CPT 501T — Analysis Of Data From CT Study Of Heart Blood Vessels To Assess Severity Of Heart Artery Disease, With Interpretation And Report (7 hospitals, — samples)
• CPT 501U — Oncology (colorectal), blood, quantitative measurement of cell-free DNA (cfDNA) (85 hospitals, — samples)
• CPT 502T — Analysis Of Data From CT Study Of Heart Blood Vessels To Assess Severity Of Heart Artery Disease, Data Preparation And Transmission (11 hospitals, — samples)
• CPT 502U — Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV (85 hospitals, — samples)
• CPT 503T — Analysis Of Data From CT Study Of Heart Blood Vessels To Assess Severity Of Heart Artery Disease, Analysis Of Fluid Dynamics (11 hospitals, — samples)
• CPT 503U — Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/np-tau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorith (84 hospitals, — samples)
• CPT 504T — Analysis Of Data From CT Study Of Heart Blood Vessels To Assess Severity Of Heart Artery Disease, Anatomical Data Review (7 hospitals, — samples)
• CPT 504U — Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism (85 hospitals, — samples)
• CPT 505U — Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism (85 hospitals, — samples)
• CPT 506T — MAC PGMT OPT DNS MEAS HFP (82 hospitals, — samples)
• CPT 506U — Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus (85 hospitals, — samples)
• CPT 507T — NEAR IFR 2IMG MIBMN GLND I&R (85 hospitals, — samples)
• CPT 507U — Oncology (ovarian), DNA, whole-genome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected (85 hospitals, — samples)
• CPT 508T — Ultrasound Measurement Of Bone Density In Shin Bone (9 hospitals, — samples)
• CPT 508U — Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection (85 hospitals, — samples)
• CPT 509T — PATTERN ERG W/I&R (82 hospitals, — samples)
• CPT 509U — Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection (85 hospitals, — samples)
• CPT 50U — TRGT GEN SEQ DNA 194 GENES (85 hospitals, — samples)
• CPT 510T — RMVL SINUS TARSI IMPLANT (85 hospitals, — samples)
• CPT 510U — Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole-transcriptome data, reported as probability of predicted molecular subtype (85 hospitals, — samples)